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Abstract
Lupus is a heterogenous multisystem autoimmune disease whereby nephritis is 
one of its most common cause of overall morbidity and mortality. Accurate, timely 
diagnosis and effective treatment in lupus nephritis (LN) remains a challenge to 
many clinicians including those who are directly involved in the daily care of these 
patients. Despite significant improvement in patients’ survival rate in recent years, 
in this era of precision medicine, there is pressing need to further improve our 
understanding and management of this disease. Our chapter would shed light on 
the key issues in LN including recent advances in our scientific understanding of its’ 
pathophysiology, major challenges and treatment strategies.
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1. Introduction
Lupus nephritis (LN) is the most common severe organ manifestation of systemic 
lupus erythematosus (SLE). It may be the presenting manifestation of SLE and 
usually arises within 5 years of diagnosis [1]. Approximately 40–70% of SLE patients 
will develop LN [2] with histopathological changes observed in most patients even 
among those without renal manifestations (known as “silent LN”; mostly with 
“milder” class I and II histologic lesions) [3, 4]. Clinical presentation of LN is highly 
variable, ranging from asymptomatic proteinuria with normal renal function to 
rapidly progressive renal failure.
Recent data demonstrates reduction in the temporal mortality trend among 
end stage renal disease (ESRD) LN patients [5]; however, the risk of progression 
to ESRD in LN remains unchanged [5, 6]. Despite significant improvement of 
outcome in this modern era, less than 50% of patients achieve complete clinical 
remission following immune suppression [7] with 10–20% of patients progressing 
to ESRD [8]. This chapter explores recent studies that have substantially contrib-
uted to our understanding of LN and provides new insights into the epidemiology, 
pathogenesis, classification criteria and management strategies of LN.
2. Epidemiology
The prevalence of SLE and LN varies based on age, gender, geographical location, 
socioeconomic status and ethnicity. There are also disproportionate differences in 
the incidence and prevalence, depending upon the validated classification criteria or 
methods of case ascertainment used.
Lupus
2
2.1 Systemic lupus erythematosus (SLE)
In a large retrospective study performed in the United Kingdom (UK) involving 
more than 7,000 SLE cases between 1999 and 2012, the overall annual incidence of 
SLE was 4.9 cases per 100,000 population per year with overall prevalence of 97 per 
100,000 population; highest in Afro-Caribbean ethnic subgroup (517 per 100,000), 
followed by the Indian subgroup (193 per 100,000) while Caucasian subgroup was 
134 per 100,000 [9]. Other studies found similar estimates with annual incidence 
between 4 and 8 cases per 100,000 population per year. Expectedly, the worldwide 
prevalence of SLE also varies between 30 to 90 cases per 100,000 population, 
highest in the African populations, lowest in Caucasians, with Hispanic and Asian 
subgroups in between the two extremes [10, 11].
All studies worldwide have demonstrated marked predominance of women in 
SLE, between 6 and 9 times higher than men. In the United States (US) and UK, 
the peak incidence was in women aged between 40 and 59 [10, 12]; in contrast, 
a population based study in Taiwan involving almost 7000 SLE patients revealed 
earlier peak incidence in women aged between 20 and 29 [13], a consistent trend 
among other studies in the Asia-Pacific region [14].
2.2 Lupus nephritis (LN)
Renal involvement occurs in 25–50% of SLE patients at the time of diagnosis 
[15]. The cumulative incidence, again, varies according to ethnicities. In a US study 
involving three ethnic subgroups, the incidence of LN was found to be the highest 
among the African subgroup (69%) followed by Hispanics (61%) and Caucasians 
(29%) [16]. In the Asia-Pacific region, the cumulative incidence of LN varies 
between 30% and 82%, lowest in Australian and highest in Malaysian populations 
respectively [14].
Despite higher overall incidence of SLE in women than in men, strikingly, renal 
involvement was found to be 50% higher in SLE men in a meta-analysis involv-
ing nearly 12,000 SLE patients across multiple countries [17]. Left untreated, LN 
carries significant morbidity and mortality, with the mortality rate estimated to 
be 6 times higher than general population. However, with the current therapeutic 
options, the 10-year survival for patients with LN can exceed 98% [18].
3. Pathogenesis
The pathogenesis of LN is complex and achieving full understanding of its patho-
physiologic mechanisms has proved challenging due to the molecular and phenotypic 
heterogeneity. Genetic predisposition, epigenetic dysregulation and environmental 
triggers are all likely to contribute to the disease expression [1, 19, 20]. Dysregulation 
of both innate and adaptive immune responses manifested by disturbance in apop-
totic cell clearance, cytokines stimulation, B-cell immunity and T-cell function leads 
to glomerular and/or tubulointerstitial injury.
Production of autoantibodies targeting self-DNA, other self-nuclear antigens 
and non-nuclear materials results from loss of immune self-tolerance and autoim-
munity in genetically predisposed individuals. Formation of immune complexes 
(ICs) may occur in circulation and deposits in various organ systems including the 
kidneys. Antibodies can also directly target in situ nephritogenic antigens at the 
major resident renal cells (mesangial cells, glomerular endothelial cells, tubular 
epithelial cells and podocytes) [21]. Co-stimulation by Fc receptors (FcRs) and 
endosomal Toll-like receptors (TLRs) leads to activation of the complement 
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system and subsequent release of cytokines and chemokines leading to renal 
tissue injury [22–25]. Anti-C1q antibodies, while not exclusive to LN, are strongly 
associated with renal inflammation and severe LN, amplifying complement 
activation in situ [26, 27].
Overactivation of 1) Interferon (IFN)-I signalling pathway, which is regulated 
by dendritic cells (DCs), interleukins (eg. IL 12/23), JAK1, TYK2 and various 
STAT proteins and 2) NFκB are both implicated early in the innate immune 
response and play major roles in the pathogenesis [28, 29]. Adaptive responses 
including persistent activation and interaction of aberrant polyclonal B and T 
cells involving multiple co-stimulatory molecules promote chronic inflammation 
and renal tissue damage. Studies have also uncovered that formation of long-lived 
memory T-cells and plasma cells that reside in survival niches in bone marrow and 
inflamed tissue render them resistant to conventional immunosuppression or B 
cell therapies [30].
B cell activation factor (BAFF)/B-lymphocyte stimulator (BLyS) promotes 
formation of tertiary lymphoid structures (TLSs) that contribute to lymphocyte 
priming and autoantibody production within the kidneys [31] while evidence in 
patients and animal models have demonstrated high levels of IL-17 producing T 
cells in LN [32]. Several other regulators of apoptosis have also been implicated in 
the development of LN including dysregulation of autophagy, BCL-2, phosphatase 
and tensin homologue (PTEN), mannose-binding lectin (MBL) and neutrophil 
extracellular traps (NETs) among several others [33–40].
More than 10 genome-wide association studies (GWAS) have been conducted 
thus far with more than 50 genes implicated involving various pathogenic mecha-
nisms in the pathogenesis of SLE, some associated with LN [2, 41]. These candidate 
genes are likely to undergo further evaluation and validation from deep sequencing 
and mechanistic studies. Mohan et al. have elegantly categorised the implicated 
genes into four functional groups; genes that influence 1) lymphocyte activation, 
particularly B cells (eg. BLK, STAT4, TNFSF4, HLA-DR) 2) innate immune signal-
ling (notably NFκB and IFN-I; eg. IKZF1, IRF5, TLR9, TNFAIP3) 3) intra-renal 
signalling (eg. ACE, KLK) and 4) handling of apoptotic material, chromatin 
and ICs (eg. ATG5, ITGAM, FCGR2A/3A/3B); genetic interaction from multiple 
categories is required for severe LN to develop [2].
The TLR7 gene, which is located at chromosome X, has recently been the focus 
of considerable research in SLE and LN. Theories regarding the contribution of 
TLR7 gene have included 1) Enhanced TLR7 protein expression in renal DCs and 
macrophages which correlated with renal disease parameters in murine models 
[42] 2) Emerging evidence that TLR7 dosage is a key pathogenic factor to the 
pathogenesis of SLE: Dillon et al. assembled the largest group consisting of 316 men 
with SLE and found high prevalence of SLE in X chromosome aneuploides such as 
Klinefelter’s syndrome (KS; 47, XXY) and de la Chapelle’s syndrome (46, XX male) 
[43] while recently, Souyris and colleagues provided proof that TLR7gene evades 
X chromosome inactivation in immune cells in women and KS men, and proposed 
this as a mechanism for the elevated risk of SLE in women and KS [44], which may 
partially explain the high preponderance of SLE in females.
4. Diagnosis and classification
Current non-invasive SLE biomarkers such as proteinuria or active urine 
sediment, serum creatinine, anti dsDNA and hypocomplementemia could not 
reliably confirm the presence, severity and/or chronicity, or predict the outcome of 
LN. Many novel biomarkers are currently being explored in the management and 
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as therapeutic target in LN; unfortunately, none so far had been utilised in daily 
clinical practice [45].
In patients suspected of LN, certain clinical and laboratory features may how-
ever predict the class of LN a patient may have. In a retrospective study analysing 
297 renal biopsies of SLE patients with some degree of proteinuria, absence of 
malar rash, negative anti-dsDNA and urine leukocytes of <5/high power field 
under microscopy are independent predictors for class II LN. Class III or IV can 
independently be predicted by younger age at diagnosis (<32 years), musculo-
skeletal involvement, hypertension, presence of anti-dsDNA, elevated creatinine 
level, absence of nephrotic range proteinuria and presence of leucocytes and 
cellular cast in urine. Older age, malar rash and low C3 level may be predictive for 
class V LN [46].
4.1 Role of renal biopsy
Renal biopsy is the gold standard for the diagnosis and current classification of 
LN. The histological findings may assist physicians to optimise therapeutic strate-
gies in individual patients, including assessing disease activity and/or chronicity for 
guidance to escalate or de-escalate immunosuppression accordingly. It is an invasive 
procedure with potential risks, most notably bleeding; however, given the lack of 
available biomarkers to identify disease activity, it remains an irreplaceable tool and 
mainstay of current management in LN.
Indication for a renal biopsy includes significant proteinuria of >0.5 g/day 
(or equivalent), certain unclear acute elevation of serum creatinine level, and in 
patients with severe disease relapse (Table 1) [47]. Biopsy is rarely done in patients 
with isolated haematuria or proteinuria of <0.5 g/day; hence, class I LN is rarely 
seen in the histology. Performed by either experienced nephrologist or interven-
tional radiologist, adequate tissue is obtained in >95% of times.
Given the location of kidney where no direct compression can be performed 
post biopsy, bleeding (as detected by routine CT scan or ultrasound post biopsy) 
was found to be common, ranging in 57–91% of patients [48]; however, the actual 
incidence of clinically important bleeding is small. Meta-analysis of 34 relevant 
studies found low rates of macroscopic haematuria (3.5%) and blood transfusion 
(0.9%), with lower rates yielded in need for interventions (0.6%) such as catheter 
insertion for bladder obstruction (0.3%) and nephrectomy (0.01%) and death 
(0.02%) [49].
The bleeding risk increases in females, use of larger needle (14-G), elevated 
serum creatinine (>176 umol/L) or acute renal failure, uncontrolled systolic blood 
pressure (>170 mmHg) [49, 50] and in patients with coagulopathies or are on 
anticoagulation/antiplatelet agents. Most serious complications are detected within 
4 hours of biopsy, and majority within 12 hours [51, 52]. Routine 1-hour post biopsy 
ultrasound for presence of haematoma to predict complication has not been shown 
to be clinically beneficial (positive predictive value of 43%; negative predictive 
value of 95%) [53].
Should biopsy May biopsy
Proteinuria >0.5 g/24 hours
Unexplained renal insufficiency
Differentiating activity vs. chronicity
Severe relapse
Isolated haematuria or pyuria
Proteinuria less than 0.5 g/24 hours
‘Protocol’ biopsy during/after treatment
Mild relapse
Table 1. 
Possible indications for kidney biopsy in SLE patient.
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The role of repeat renal biopsy in LN flares is controversial. In essence, a repeat 
biopsy is required if it may change management; for example, this is particularly 
true in a patient with stable renal function who developed sudden deterioration of 
creatinine associated with active urine sediment. This may reflect the possibility of 
crescentic glomerulonephritis (GN) that warrants stronger immunosuppression. 
During LN flare, histological transformation is more likely to occur if the initial 
histology revealed non-proliferative disease (initial class II); although, many would 
still have persistent active lesions in proliferative disease [54, 55].
Renal biopsy may also be considered to determine disease chronicity in patients 
with persistent proteinuria and lower glomerular filtration rate (GFR), which 
warrant de-escalation of immunosuppression. It is well documented that repeat 
biopsies lead to change to immunosuppression in more than half of the cases [55].
Decision to stop maintenance immunosuppression in LN is often challenging 
and some researchers perform ‘protocol biopsies’ after a period of complete clinical 
remission to guide withdrawal of treatment. Its’ value however is still debatable, 
as studies mostly looked at the prognosis based on the histological features [54]. In 
a study by De Rosa et al., 36 LN patients on immunosuppressive therapy for more 
than 3 years and in clinical remission (proteinuria <0.5 g/day) were re-biopsied. 
Regardless of the results of biopsy, the immunosuppressive medications were 
tapered down. Those patients with residual activity in histology had higher chance 
of relapses upon reducing therapy [56], which supports histology-based approach 
in treatment withdrawal.
4.2 Classification criteria
4.2.1 SLE and renal involvement
The revised American College of Rheumatology (ACR) 1997 criteria specifies 
that a patient can be diagnosed with SLE if 4 of 11 criteria are met at any interval of 
observation (Table 2). Renal involvement can be considered if patient developed 
proteinuria of >0.5/day or appearance of cellular cast (red cells, haemoglobin, gran-
ular, tubular or mixed) [57]. The 2012 Systemic Lupus International Collaborating 
Clinics (SLICC) criteria divided SLE features into 11 clinical and 6 immunologic 
criteria, where SLE can be fulfilled by a) biopsy-proven LN in presence of ANA or 
anti-DNA antibodies or b) meeting ≥4 of 17 criteria, with at least 1 criterion from 
each division [58].
European League Against Rheumatism (EULAR)/ACR published a new set of 
criteria for SLE diagnosis in 2019 [58]. It employs the strategy that ANA must be 
positive for the diagnosis to be considered, followed by 10 domains with different 
individual weightage; diagnosis can be made if total score reaches 10 points, again 
with renal involvement carrying a high weight between 4 and 10 depending on the 
renal manifestations (Table 2) [59].
4.3 Diagnosis of lupus nephritis
The clinical presentations of LN may differ ranging from asymptomatic hae-
maturia to rapidly progressive GN. All patients with SLE should have urinalysis 
checked on regular basis to detect renal involvement. Presence of significant pro-
teinuria would trigger the need for a renal biopsy, although many would perform 
biopsies for reasons such as persistent haematuria and elevated serum creatinine 
[54]. Biopsy is critical to distinguish between active nephritis, non-glomerular 
pathology of SLE (such as tubulointerstitial nephritis or thrombotic microangi-
opathy) and disease chronicity (such as interstitial fibrosis, tubular atrophy and 
Lupus
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glomerulosclerosis). Importantly, biopsy findings should be interpreted and  
correlated carefully with patients’ clinical features and serology.
In an analysis by Ishizaki et al. of 48 SLE patients who had renal biopsies but 
no urine abnormality, 36 patients were identified to have some morphologic 
changes. Although majority had class I/II (72%), six (17%) patients were found 
to have class III/IV LN [60]. LN has characteristic histological features that 
differ from other glomerular pathology and may involve lesions in the glomeru-
lar, vascular or tubulointerstitial structures. Analysis of 860 renal biopsies by 
Kudose S et al. confirmed 5 histopathological features of LN; 1) “full-house” 
staining by immunofluorescence (IF) 2) intense C1q staining 3) extraglomerular 
deposits 4) combined subendothelial and subepithelial deposits and 5) endothe-
lial tubuloreticular inclusion [61].
ACR 1997 SLICC 2012 ACR 2019
4 out of 11 criteria 4 out of 17 criteria, with at 
least 1 from each domain
Fulfil the entry criterion, followed by 10 
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Criteria for SLE diagnosis based on different criteria.
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The first published classification of glomerular changes in LN was formulated 
in 1974 under the auspices of the World Health Organisation (WHO; Table 3). 
It divides glomerular changes into five classes, which became the basis of today’s 
classification. Class I applies to biopsies with no detectable changes in glomeruli; 
class II for pure mesangial disease, class III and IV were defined as proliferative 
disease, with the former affecting <50% of glomeruli and latter >50%. Class V was 
for membranous changes. This was modified in 1982, which include replacement of 
“focal proliferative” term to “focal segmental” GN and addition of a new category, 
class VI, which denoted advanced sclerosing GN (Table 3) [62].
Due to inconsistencies and ambiguities of the available classification criteria, 
under the auspices of International Society of Nephrology/Renal Pathology 
Society (ISN/RPS), a new classification of LN was proposed in 2003 [63]. 
While keeping the overall architecture of the 6 classes in LN, several significant 
changes were made and emphasis was given to standardisation of biopsy reports. 
Definition of class I was changed to normal glomeruli under light microscopy 
but with mesangial deposits under IF. There was also subdivision of class IV into 
diffuse segmental (IV-S) or diffuse global (IV-G), while terms active (A), chronic 
(C) or acute-on-chronic (A/C) lesions were also introduced.
The ISN/RPS classification for LN was revised in 2018; among the changes 
include elimination of the subdivisions of class IV into segmental (IV-S) or global 
(IV-G), replacement of previous denomination of active (A) and chronic (C) to 
the actual activity indices (maximum score for activity index is 24 and chronicity 
index is 12; Table 4), and preference for the term “hypercellularity” rather than 
“proliferation” [64]. The lack of classification for tubulointerstitial and vascular 
involvement in LN will be addressed and revised after the next (phase 2) interna-
tional nephropathology working group evaluation and recommendations [64].




Minimal mesangial lupus nephritis
Class I














Focal lupus nephritis a, b
Class III





Diffuse segmental (IV-S) or global 
(IV-G) lupus nephritis a, b
Class IV









Advanced sclerosing lupus nephritis
Class VI
Advanced sclerosing lupus 
nephritis d
*WHO: World Health Organisation; ISN/RPS: International Society of Nephrology/Renal Pathology Society; a: 
indicate the proportion of glomeruli with active and sclerotic lesions; b: indicate the proportion of glomeruli with 
fibrinoid necrosis and cellular crescents; c: may occur in combination with class III or IV; d: activity and chronicity 






5.1 Current management strategies
Early treatment in LN has been shown to improve outcome; however, effective 
management remains a challenge. It requires a multidisciplinary team approach 
(MDT), ideally by rheumatologists, nephrologists and nephropathologists. The 
cornerstone of treatment entails corticosteroids, antimalarial, and steroid-sparing 
agents (conventional immunomodulators and/or biological therapies) tailored to 
individual patients based upon histological class and severity to achieve rapid resolu-
tion of inflammation, proteinuria <0.5–0.7 g/day by 12 months (or up to 24 months 
in baseline nephrotic range proteinuria) [47] and prevention of relapsing episodes.
5.1.1 Induction phase
While there is little agreement for class II LN, in active proliferative class III, IV 
and pure membranous class V (with nephrotic range proteinuria or proteinuria >1 g/
day despite optimal use of renin-angiotensin-aldosterone system (RAAS) blockers), 
the current recommendation for initial induction treatment options include either 
low-dose intravenous cyclophosphamide (CYCi; 500 mg fortnightly infusions for 
3 months) or mycophenolate mofetil (MMF; 2-3 g/day or mycophenolic acid (MPA) 
at equivalent dose) [47, 65–68]. This is combined with high-dose pulsed intravenous 
methylprednisolone followed by oral corticosteroid taper. High-dose CYCi is reserved 
for patients with severe LN due to its’ various unfavourable side effects (mainly severe 
cytopenias and infection, cystitis, ovarian failure, cervical dysplasia and malignancy).
The use of calcineurin inhibitors (CNIs) namely tacrolimus (TAC) and cyclo-
sporin (Cys) either as monotherapy or as part of a multitarget regimen therapy 
(with MMF/MPA and glucocorticoid) may have a favourable efficacy to induce 
remission. Meta-analysis in 2017 which included 45 induction trials of diverse 
participant background confirmed superior efficacy in induction by multitarget 
Items Score Comment
Activity Index
Endocapillary hypercellularity 0 to 3+ 0 to 3+ based on % involvement of glomeruli 
or tubulointerstitium. 0 = none, 1+ = <25%, 
2+ = 25–50%, 3+ = > 50%.
Neutrophils/karyorrhexis 0 to 3+
Fribrinoid necrosis 0 to 3+ (x2)
Hyaline deposits 0 to 3+
Cellular/fibrocellular crescents 0 to 3+ (x2) Double weightage for fibrinoid necrosis and 
cellular/fibrocellular crescent.
Interstitial inflammation 0 to 3+
TOTAL 24
Chronicity Index
Total glomerulosclerosis score 0 to 3+ 0 to 3+ based on % involvement of glomeruli 
or tubulointerstitium. 0 = none, 1+ = <25%, 
2+ = 25–50%, 3+ = > 50%.
Fibrous crescent 0 to 3+
Tubular atrophy 0 to 3+
Interstitial fibrosis 0 to 3+
TOTAL 12
Table 4. 
Modified NIH activity and chronicity scoring system (ISN/RPS 2018).
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therapy compared to CYCi [69]; however, safety concern with its long term use 
mainly of chronic progressive irreversible nephrotoxicity remains an issue [70].
5.1.2 Maintenance phase
In the maintenance phase of treatment where less intensive therapy is required, 
MMF (1-2 g/day or MPA at equivalent dose) or azathioprine (AZA) are the drugs 
of choice [47, 71, 72] (with or without low dose <7.5 mg/day corticosteroid), 
depending on the induction regimen and plan for pregnancy. Hydroxychloroquine 
(HCQ ) is recommended for all LN patients in the absence of contraindications 
[47]. Due to possible ocular toxicity, the dose should not exceed 5 mg/kg body 
weight and should be adjusted in patients with renal and liver disease, with regular 
ophthalmological screening.
5.1.3 Refractory lupus nephritis
Rituximab (RTX), although off-label, is not only indicated in patients refractory 
to conventional therapy or after great cumulative dose of CYCi, but also in patients 
of child bearing age [47, 73, 74]. Another B-cell targeting therapy which inhibits 
BlyS, Belimumab has recently been proven to be beneficial as add-on to the stan-
dard of care (SOC) therapy (mainly in the MMF subgroup) with primary efficacy 
renal response seen by week 24 and sustained through week 104 [75].
It is recommended not to discontinue immunosuppression too early as most 
renal flares occurs during this period. Treatment withrawal can be considered in 
patients with sustained complete remission for 3–5 years, with treatment deescala-
tion prior to complete withrawal of therapy [47]. Close monitoring of patients and 
management of co-morbidities including blood pressure (BP) control, treatment 
of hyperlipidaemia with statins and proteinuria with RAAS blockers are important, 
while vaccination against influenza and Streptococcus pneumoniae are strongly 
recommended. Repeat renal biopsy may be considered to guide the duration of 
maintenance immunotherapy and may be required in patients with incomplete 
response or recurrent LN flares [47, 65].
5.2 Future novel therapeutic options
Developing more effective treatment strategies in LN remains a priority among 
clinicians and researchers across the globe; however, major challenges exist in 
its advancement due to the complex pathophysiology and heterogeneity, which 
directly impact on clinical trial design and overall outcome. Moreover, most trials 
are conducted with background therapy, which is difficult to control during the 
study and its subsequent analysis, as there is no clear definition in the SOC [76]. 
Notwithstanding this, extensive therapeutic strategies have emerged with wide 
array of novel treatments to improve patient outcomes. Major trend in current 
treatment landscape for LN focuses on reduction of steroid use.
There is gathering evidence, especially in more recent times, documenting the 
successful safe use of Belimumab, a monoclonal antibody (mAb) directed against 
BlyS as an add-on therapy in LN, especially in patients with low complement levels 
and high anti-DNA antibodies [75, 77]. It is the first targeted therapy and currently 
the only biological agent approved specifically for LN. There is also increasing 
interest in the sequential use of two B-cell targeting agents, RTX and Belimumab in 
active LN [78, 79] with a phase III trial already underway [80]. The rationale for this 
approach is due to the hypothesis that their co-administration may enhance deple-
tion of circulating and tissue-resident autoreactive B cells.
Lupus
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Another potent BAFF-inhibitor, Blisibimod, was associated with reduction in 
steroid use, decreased proteinuria and biomarker responses in a multinational 
phase III trial [81]. Tabalumab, a selective mAb that neutralises both membrane and 
soluble BAFF, despite having the same therapeutic class, on the contrary did not 
yield the expected positive statistical significance results in two phase III studies 
involving SLE patients; however, only approximately 10% of patients in these stud-
ies had renal involvement [82, 83].
Voclosporin, a novel next generation CNIs (an analogue of cyclosporin) with 
enhanced calcineurin inhibition, better safety profile and consistent predictable 
dose response, despite initial safety concerns in the prior phase II study [84], has 
recently been demonstrated in a phase III trial to be highly effective for treatment of 
LN when combined with MMF, with acceptable safety profile, at least for the short 
term (52 weeks) [85]. More importantly, it has just received the approval by the 
United States’ Food and Drug Administration (FDA) on the 22nd of January 2021, 
making it the only second targeted therapy approved specifically for LN [86].
There is emerging theoretical evidence for targeting autoantibody-secreting 
long-lived plasma cells (PCs) that recide in dedicated survival niches in the bone 
marrow or inflammed tissues of LN patients. Bortezomib, a proteasome inhibitor 
has been shown to be effective in both animal models and real-world setting but is 
limited by treatment related toxicity [87–89]. Recently, Ostendorf and colleagues 
have demosntrated succesful use of Daratumumab, a mAb that targets CD38 and 
depletes PCs with acceptable safety profile in a patient with refractory LN [90]. The 
experience of its use however is still limited and more data will be required.
Obinutuzumab, a novel anti-CD20 mAb demonstrated encouraging sustained 
18-months B-cell depletion and renal response in a phase II trial with further evalu-
ation in phase III trial underway (can be accessed at ClinicalTrials.gov with identi-
fication number: NCT04221477) [91]. BI 655064 (anti CD40 mAb; NCT02770170) 
has recently completed a phase II trial as add-on therapy to SOC treatment in active 
LN and awaiting evaluation. Other biological agents currently undergoing clini-
cal trials in the treatment of LN include Anifrolumab (Type I IFN receptor mAb; 
NCT02547922) in phase II, while Dapirolizumab (pegylated anti CD40 ligand; 
NCT04294667) and Secukinumab (anti-IL-17 mAb; NCT04181762) are both in 
phase III trials [92].
A pipeline of novel agents in LN are being developed or asssesed in clinical trials 
including Ravulizumab (novel anti complement C5 antibody; NCT04564339), 
Guselkumab (IL-23 inhibitor; NCT04376827), Itolizumab, (anti CD6 antibody; 
NCT04128579), KZR-616 (proteasome inhibitor; NCT03393013), Iguratimod 
(novel small molecule; NCT02936375), and BMS-986165 (novel tyrosine kinase 2 
(TYK2) inhibitor; NCT03943147) among many others [92].
Targeting the JAK/STAT signalling pathway with Tofacitinib, or CP-690, 550 
have been shown to be effective in murine LN model and may potentially serve 
as therapeutic target in LN [93, 94]. Successful Bruton’s Tyrosine Kinase (BTK) 
inhibition in several studies involving mice LN models supports Kong et al. finding 
of significantly upregulated BTK expression in glomerulus of LN patients and may 
potentially be a therapeutic target in LN [95–97].
Despite looking promising in SLE, a placebo-controlled phase II/III study to 
evaluate Atacicept (recombinant fusion protein that inhibits BAFF/BLyS or APRIL) 
in combination with MMF and corticosteroids in active LN patients was prema-
turely terminated due to unexpected substantial decline in serum IgG and serious 
pneumonia infections in Atacicept-treated patients [98, 99]. Abatacept, a recom-
binant fusion protein co-stimulation modulator, trialled as add on to SOC in LN 
failed the primary end point of a phase III trial despite demonstarating more rapid 
reduction of proteinuria and earlier sustained remission [100].
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Newer treatment paradigms showing promising results include succesful use 
of autologous haematopoietic and allogeneic mesenchymal stem cell transplanta-
tions for LN in animal studies and among Asian patients [101–106] while Yu et al. 
demonstrated in vitro the protective role by vitamin D in podocyte injury induced 
by autoantibodies from patients with LN and suggested possible role of vitamin D 
as a novel therapy target in LN [107].
6. Special considerations
6.1 Pregnancy and lupus nephritis
6.1.1 Pre-pregnancy
Women of childbearing age with LN should understand and be counselled about 
the potential risks of pregnancy, even if she is in complete remission. Age, previ-
ous pregnancy complication, duration from last LN relapse, medication exposure, 
treatment adherence, blood pressure (BP) control and current disease status are 
among the important factors that may determine the outcome of future pregnancy. 
Baseline complement levels, antibody status for dsDNA, SS-A and SS-B, presence 
of antiphospholipid antibodies (aPL; notably lupus anticoagulant antibody) and 
urinalysis for proteinuria should be obtained prior to pregnancy.
Possible maternal complications include flare of nephritis, uncontrolled hyper-
tension, pre-eclampsia, risk of Caesarean section, worsening renal function and 
thrombosis. Foetal risks include prematurity, growth retardation, congenital heart 
block and intrauterine death [108]. Patients with active disease at conception, 
uncontrolled hypertension, proteinuria of >1 g/day and abnormal renal function 
have the highest risk for complications; therefore, good control of disease prior to 
pregnancy is critically important to optimise pregnancy outcome and ideally the 
pregnancy should be planned.
Patients on MMF should be transitioned to pregnancy-safe immunosuppressive 
drugs such as AZA or TAC, while HCQ should be continued throughout pregnancy. 
MMF exposure especially after the first trimester increases the risk of miscarriage 
and congenital malformation [109], and practically should be stopped at least 
3–6 months prior to conception to ensure disease control is maintained with the 
new agent(s) [47]. CYC is also teratogenic, associated with premature ovarian 
failure and increases miscarriage rate [110].
RAAS blockers should ideally be stopped before conception due to possible tera-
togenicity risk [111]; however, later publications seemed to suggest that they may be 
safe to be used until pregnancy is confirmed [112]. This is important especially for 
those who have residual proteinuria as attempt to conceive may take months or even 
years of effort. Stopping RAAS blockers early on in these patients would essentially 
exclude them from its’ benefits.
6.1.2 During pregnancy
Multidisciplinary team approach is important during pregnancy and should 
ideally involve the obstetrician, neonatologist, nephrologist and rheumatologist. 
Majority of patients (80%) with quiescent LN would have successful pregnancies 
[113]; however, about a third may relapse during pregnancy [108]. Identification 
of patients who are at higher risk is important when pregnancy begins, as these 
patients will require closer observation to ensure good maternal and foetal out-
comes (Table 5) [109, 114–118].
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During early pregnancy, BP would usually remain normal even in patients 
who required antihypertensive before pregnancy. Gradually, BP may rise as preg-
nancy progresses, requiring reintroduction of hypertensive medications such as 
labetalol, methyldopa or nifedipine. BP control should be targeted to be less than 
140/90 mmHg [119]. As these patients are at higher risk to develop pre-eclampsia, 
high dose calcium supplementation and aspirin should be prescribed before enter-
ing 16 weeks of gestation [120, 121]. Ultrasound screening including uterine and 
umbilical artery Doppler to detect early signs of placental insufficiency may be 
performed at regular interval, especially in high-risk patients.
Hydroxychloroquine is safe during pregnancy and discontinuation has been 
associated with lupus flare. It also significantly reduces the risk of foetal congenital 
heart block in patients with positive SS-A (anti-Ro) [116]. Other drugs for consider-
ation in LN and compatible with pregnancy include AZA, CNIs (TAC, Cys), plasma 
exchange and intravenous immunoglobulins. Data on RTX in pregnancy is limited, 
although some clinicians have used it safely in early trimester without apparent 
complication [122]. LN flare during pregnancy can be treated with drugs mentioned 
above and with addition or increased dosage of steroid. Pulsed intravenous methyl-
prednisolone may be given during severe flares, followed by oral prednisolone [114]. 
While use of steroid is associated with elevated BP and new onset diabetes, it is prob-
ably not related to cleft lip and palate as previously thought [123, 124] (Table 6).
Baseline risk assessment Possible complication
Active disease during conception Pregnancy loss, pre-eclampsia, IUGR, prematurity [114]
Proteinuria >1 g/day Worsening renal function, pre-eclampsia [115]
Uncontrolled hypertension Pregnancy loss, IUGR, prematurity, pre-eclampsia [114]
Presence of SS-A antibody Neonatal lupus (congenital heart block) [116]
History of recent acute kidney injury Pre-eclampsia, IUGR and prematurity [117]
Chronic kidney disease Worsening renal function, prematurity, IUGR, preeclampsia [118]
Mycophenolate exposure during 
pregnancy
Miscarriage and embryopathy involving ear, mouth, finger and 
ocular malformation [109]
*IUGR: Intra-uterine growth retardation.
Table 5. 
Baseline risk assessment during pregnancy.
Medication Pregnancy Breastfeeding
Cyclophosphamide Increased risk of teratogenicity, especially in 1st trimester May cause infants’ bone 
marrow suppression
Mycophenolate Increased risk of congenital malformation and miscarriage Limited data, not 
recommended
Azathioprine Relatively safe. Alternative to mycophenolate Relatively safe
Hydroxychloroquine Relatively safe. Improve outcome in antiphospholipid syndrome Relatively safe
Glucocorticoids Increase risk of hypertension, preeclampsia, GDM. May have 
neutral effect on cleft lip and palate
Relatively safe
Calcineurin inhibitor Increase risk of high blood pressure and diabetes. Relatively safe Relatively safe
Rituximab Limited data. No teratogenic effect in animal. 1st trimester use 
may be possible.
Limited data
Immunoglobulin Safe in pregnancy. Headache & rash common side effect Relatively safe
*GDM: Gestational diabetes mellitus.
Table 6. 
Summary of immunosuppressive drugs during perinatal period.
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Differentiating between pre-eclampsia and LN flare in pregnancy may be 
difficult, especially after 20 weeks gestation. Features like proteinuria, high BP, 
thrombocytopenia and renal impairment are common in both conditions. Red cell 
cast in urine, abnormal level of complements and anti-dsDNA may point toward 
LN flare [125]. Elevated soluble fms-like tyrosine kinase 1 (sFlt1)/placental growth 
factor (PlGF) ratio may assist in predicting pre-eclampsia [126, 127] although not 
commonly available in clinical practice.
Renal biopsy may be required during pregnancy but poses increased risk of 
complications. In a systematic review involving data on renal biopsies performed 
during pregnancy, overall complication rate was higher at 7%, compared to 1% 
when performed post-partum. Importantly, 4 biopsies during pregnancy had major 
bleeding complications that required blood transfusion, with median gestational 
age of 25 weeks; hence, biopsy should only be considered early during the course of 
pregnancy when results may lead to changes in therapy. Biopsy should be consid-
ered if LN flare is suspected and to distinguish it from pre-eclampsia, with finding 
of glomerular endotheliosis would suggest the latter [128].
Multidisciplinary team approach and patients’ engagement are prudent during 
severe LN flare, as pregnancy termination may be considered with risks and ben-
efits weighed carefully, so that patient can be treated with urgent cytotoxic drugs. 
Overall rate for preterm delivery and Caesarean section are higher in patients with 
LN. For patients with non-active disease, delivery at term should be aimed. In those 
likely to deliver prematurely, dexamethasone should be given to accelerate foetal 
lung maturation. Delivery should be aimed after 34 weeks to minimise neonatal 
adverse outcomes; nonetheless, this strategy relies on the overall clinical picture. 
Timing of delivery is determined by usual obstetric indications and risk of renal 
deterioration. Mode of delivery does not seem to affect maternal renal function and 
again should be based on the usual indications accordingly [129].
6.1.3 After pregnancy
The WHO recommends breastfeeding for all babies until 6 months of age, even 
in patients on immunosuppressive therapy. Although studies found trace amount 
of immunosuppressives excreted into breast milk, the amount absorbed by infant 
is negligible and do not exert any clinical effect [130]. Hence, immunosuppressives 
deemed safe during pregnancy such as corticosteroid, AZA and CNIs can be safely 
taken during breastfeeding [114]. Post-partum, regular antihypertensive drugs such 
as amlodipine or bisoprolol can be reinstated and RAAS blockers such as enalapril 
or captopril can be safely used during breastfeeding [131] (Table 6).
Postpartum risk of thromboembolic disease increases in SLE especially in active 
LN patients with nephrotic-range proteinuria. Preventative measure with heparin 
during postpartum period is controversial, but may be considered in active LN 
patients with risk factors such as advanced age, obesity, Caesarean section delivery, 
and pre-eclampsia [132]. For patients with chronic kidney disease and significant 
proteinuria during pregnancy, careful monitoring after delivery is required as 
decline in renal function may accelerate within 6–12 months postpartum, despite 
having stable renal function during pregnancy [133].
6.2 Renal transplantation in lupus nephritis
Approximately 10–20% of patients with LN will progress to ESRD, with young 
female of African ancestry having the highest risk [8, 134]. In general, outcome 
for renal transplant is better compared to dialysis particularly with preemptive 
transplantation, including in patients with LN [135]. However, many patients 
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may not be in complete remission despite dialysis initiation, making preemptive 
transplantation difficult. Current guidelines suggest that clinical lupus activity 
and ideally, serologically should be quiescent for 6 months and on no or minimal 
immunosuppression prior to transplantation [47, 136]. Even if on dialysis, the wait-
ing time for transplant should be maximally shortened to reduce potential risk of 
graft failure [137].
Although the benefit of transplantation is clear, earlier studies have suggested 
that LN patients may have worse survival outcome compared to ESRD patients of 
other aetiologies; however, more contemporary studies seem to abrogate this find-
ing [138]. Clinically relevant recurrence rate of SLE post transplantation is less than 
5%, but it increases the risk of graft failure [136]. The rate may even be higher if 
electron microscopy finding is included and protocol biopsy implemented; never-
theless, the lower rate is probably due to the similar immunosuppressive therapy 
used in both transplant recipient and active LN.
During pre-transplant evaluation, particular attention should be given to 
screening of aPL as its’ presence increases the risk of graft thrombosis. Patients 
with APS would require careful consideration of perioperative anticoagulation to 
prevent graft loss. Presence of anti-dsDNA or low complement level is not a predic-
tor for renal transplant outcomes. SLE patients have higher risk for cardiovascular 
mortality hence will require careful cardiac evaluation prior to transplantation 
[138]. Recurrence of LN after transplantation can be treated by increasing the dose 
of the immunosuppressive drugs already being used post transplant. CYC may be 
considered in severe or aggressive disease while RTX has been used in resistant 
cases [139].
There is concern in LN patients of having higher risk to develop cancer with 
prolonged exposure to immunosuppression. Previous exposure to CYC doubles 
the risk for cancer post transplantation, primarily of the skin [140]. Prior use 
of immunosuppressive therapies before transplant also increases the risk for 
non-Hodgkin’s lymphoma, anogenital, breast, renal and bladder cancers [141, 
142]. Furthermore, prolonged corticosteroid exposure in transplanted SLE 
patients should adhere to the screening and treatment recommendations on bone 
health [143].
7. Conclusion
Emerging insights into the heterogenous immunopathogenesis of LN have lead 
to novel, tailored therapeutic options, resulting in significantly better disease con-
trol and prolonged remission among patients; nonetheless, more in-depth studies 
are required to better understand the pathogenesis while novel therapies continue 
to be tested. The advent of signature biomarkers show promise in diagnosis, 
evaluation and management of LN and will continue to be validated for meaning-
ful real-world application. Timely diagnosis, prompt treat-to-target treatment, 
MDT approach and adherence to therapy are important factors to preserve renal 
function, prevent disease progression and significantly improve patients’ overall 
outcome.
Better understanding of disease pathways and discoveries with subsequent 
validation of biomarkers will provide opportunity for improvement in early detec-
tion, prognostic and disease severity prediction, subgroups stratification, treatment 
adherence assessment, and decision for best treatment option in a timely manner. 
Studies targeting a single organ or specific subgroup with similar disease sever-
ity, duration and background SOC therapy will assist in better assesment of drug 
effectiveness and accelerate drug development in LN.
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